Xigen S.A., Swiss Developer of Therapeutic Peptides, Raises $20 Million in Series B Funding  
11/20/2009 7:54:55 AM

Bookmark and Share -- Xigen, a Swiss biopharmaceutical company developing innovative cell-penetrating peptides with high stability and specificity for a broad range of therapeutic indications, announced today the completion earlier this year of a Series B financing round in which it raised USD 20 million (CHF 20 million) from existing investor Tilocor Life Science.